Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed or recurrent epidermoid cancer of the head and neck~* Requires more than minimal therapy for treatment~* Able to read and write in English~* Willing to use an effective form of birth control throughout the study~Exclusion Criteria:~* Meets MINI criteria for major depression, schizophrenia, or bipolar illness or scores 24 or less~* Suicidal or psychotic~* Current allergy or hypersensitivity to citalopram or other SSRIs~* Treated with monoamine oxidase inhibitors 14 days prior to study entry~* Use of antidepressants within 1 week of study entry~* Pregnant or breastfeeding~* History of an adequate cancer operation, radiation, or chemotherapy within 6 months of study entry~* Diagnosed with melanoma or lymphoma cancer of the head and neck~* Currently participating in another research study involving a therapeutic intervention

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): Participants will receive treatment with escitalopram
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive treatment with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).